Novo Nordisk gets PhIII hemophilia trials for a Roche rival back on track after completing work-around on blood clot threat
After abruptly shutting down three hemophilia studies back in March due to serious safety issues, Novo Nordisk is getting things going again.
The Danish …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
